OrganOx appoints John Liddicoat M.D. as Non-Executive Director to the Board
OrganOx, a world leader in normothermic machine perfusion (NMP), today announces the appointment of Dr. John Liddicoat M.D. as Non-Executive Director to the Board.
"I am delighted to be joining OrganOx in the wake of FDA approval. This Company is at the start of its commercial journey in the US and based on my experience of ground breaking medical devices, I can see tremendous potential for this technology to transform the liver transplant sector and in a number of applications beyond liver transplantation" said John.
Executive Chairman of the Board, Dr. Oern Stuge said, "As an M.D. and former Medtronic EVP, John is very informed about the MedTech sector globally. I speak on behalf of the whole Board when I say we very much look forward to working with John as we take the Company forwards to the next level."
Dr. John Liddicoat is a healthcare executive with over 20 years of relevant, global healthcare experience. Most recently, John served on Medtronic's Executive Committee as Executive Vice President and President of the Medtronic Americas Region and Medtronic's Enterprise Technology and Innovation function.
Known as a transformational leader focused on execution, John has centered his career on innovation-driven growth to improve healthcare around the world and drive shareholder value. He has taken products from concept through product development to global commercial launch. Prior to joining Medtronic, John was a cardiac surgeon and Assistant Professor at Harvard Medical School, and served as a consultant to venture capital firms and early-stage medical device companies.